礼来:关键次要终点显示,75%服用Orforglipron最高剂量的参与者糖化血红蛋白达到≤6.5%

美股速递
Aug 26

礼来公布临床试验结果显示,在关键次要终点方面,75%服用Orforglipron最高剂量的试验参与者其糖化血红蛋白(A1C)水平达到了6.5%或以下的目标值。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10